Varenzin-Ca1 Oral Suspension for Cats 25mg/mL

Description

Approximately 30-65% of cats with chronic kidney disease (CKD) will also develop anemia.1 Varenzin-CA1 is a revolutionary new treatment in the fight against non-regenerative anemia in cats with CKD.

Varenzin-CA1 is the FIRST and ONLY FDA conditionally approved option for the treatment of non-regenerative anemia in cats with CKD, setting the new standard of care for cats suffering the debilitating effects of this often fatal disease.

• A first of its kind in veterinary medicine, Varenzin-CA1 stimulates a cat’s body to create its own erythropoietin
• Reasonable expectation of efficacy with minimal side effects
• Approved for convenient at-home treatment; no in-clinic injections needed
• No costly and inconvenient extra label use of erythropoietin stimulating agents (ESAs)

Indication

Control of nonregenerative anemia associated with CKD in cats

Active ingredient

Molidustat

Formulation

Oral suspension

Varenzin-CA1 Dosing Information